EL PAÍS takes a journey through Ávila, Soria, Segovia and Valladolid in search of the places that captivated the brilliant ...
The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...
Candel Therapeutics (CADL) stock rises as the company updates results from an ongoing mid-stage trial for its lead candidate, CAN-2409 in lung cancer. Read more here.
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revvity (RVTY – Research Report) and Candel Therapeutics (CADL – Research Repo ...
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...
More than 90 students from Old Forge, Tunkhannock Area and Susquehanna Community school districts participated in hands-on ...
Candel Therapeutics Inc (NASDAQ:CADL),, a clinical-stage biopharmaceutical company, will present new data from its phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results